Lucinactant
Clinical data | |
---|---|
Trade names | Surfaxin |
ATC code | |
Identifiers | |
CAS Number | |
UNII |
Lucinactant (trade name Surfaxin) is a liquid medication used to treat infant respiratory distress syndrome.[1] It is a pulmonary surfactant for infants who lack enough natural surfactant in their lungs. Whereas earlier medicines of the class, such as beractant (Survanta & Beraksurf), calfactant (Infasurf), and poractant (Curosurf), are derived from animals, lucinactant is synthetic. It was approved for use in the United States by the U.S. Food and Drug Administration (FDA) on March 6, 2012.[2]
Medical uses
Lucinactant is indicated to improve lung function and reduce duration and risk of
Chemistry
Lucinactant contains the peptide sinapultide (KL4 acetate, KLLLLKLLLLKLLLLKLLLLK), dipalmitoylphosphatidylcholine, 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoglycerol (as the sodium salt), and palmitic acid.[citation needed]
History
The scientific groundwork for lucinactant was laid in the laboratory of Charles Cochrane at The
Legal status
Lucinactant is listed as an Orphan Drug Product by the US Food and Drug Administration for several conditions:[9][10]
- 07-30-1996 Treatment of meconium aspiration syndrome in newborn infants
- 07-17-1995 Treatment of acute respiratory distress syndrome in adults.
- 05-23-2006 Prevention of bronchopulmonary dysplasia in premature infants
- 10-21-2005 Treatment of bronchopulmonary dysplasia in premature infants.
- 10-18-1995 Treatment of respiratory distress syndrome in premature infants.
Clinical trials in Latin America were criticized for protocol based in potentially unethical principles.[11] A placebo was used and considered ethical by design since infants born in Latin America usually do not have access to life saving treatment. The intent of Discovery Labs was always to market Surfaxin in the United States, implying burdens on the Latin American children that outweighed the benefits.[citation needed]
References
- ^ "Surfaxin". Discovery Labs. Archived from the original on April 20, 2009.
- ^ "FDA approves Surfaxin to prevent breathing disorder in premature infants". Fda.gov. 2012-03-06. Retrieved 2012-10-20.
- ^ "POPG, a Key Component of Discovery Labs' KL4 Surfactant, Identified as a Novel Anti-Viral Therapeutic Approach". Archived from the original on January 22, 2010.
- PMID 10508806.
- ^ S2CID 6843316.
- PMID 12042546.
- ^ "Scripps Research Discoveries Lead to Newly Approved Drug for Infant Respiratory Distress Syndrome". Scripps.edu. 2012-03-06. Retrieved 2012-10-20.
- ^ "Pharmaceutical News - Discovery Labs Turns Focus To Surfaxin Market Strategy - October 20, 2012". Pharmacy Choice. Retrieved 2012-10-20.
- ^ "List Of Orphan Products Designations And Approvals". Google2.fda.gov. Retrieved 2012-10-20.
- ^ "US FDA grants "orphan drug" status for sinapultide (Surfaxin) for chronic lung disease in premature infants". Nelm.nhs.uk. Archived from the original on 2010-04-14. Retrieved 2012-10-20.
- PMID 11238147.